Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis?

Journal of Chemotherapy

Volumn 22, Issue 5, 2010, Pages 345-355

  Schito, G C ^a   Gualco, L ^a   Naber, K G ^b   Botto, H ^c   Palou, J ^d   Mazzei, T ^e   Marchese, Anna ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FOCH HOSPITAL   (France)

^d FUNDACIÓ PUIGVERT   (Spain)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Breakpoints; CLSI; EUCAST; MIC; Urinary tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; MECILLINAM; NITROFURANTOIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CYSTITIS; ESCHERICHIA COLI; FEMALE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 78651380870     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.5.345     Document Type: Article

References (14)

1. GrabeM, Bishop MC, Bjerklund-Johansen TE, et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Arnhem, The Netherlands: EAU; 2006. http://www.uroweb.org [accessed 10 December 2008].
2. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003;51:69-76.
3. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002;34:1165-1169.
4. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54:1164-1178.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S19 (2009) Wayne, PA, USA: CLSI.
6. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available at http://www.eucast.org
7. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard M7-A7.Wayne, PA: CLSI; 2006.
8. Gordon KA, Jones RN; SENTRY Participant Groups (Europe, Latin America, North America). Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2003 ;45:295-301.
9. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 2008;61:621-628.
10. Kahlmeter G, Brown DF, Goldstein FW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52:145-148.
11. Kahlmeter G. EUCAST procedure for harmonizing and defining breakpoints. http://www.srga.org/EUCAST/bpsetting.htm (17 July 2007, date last accessed).
12. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-758.
13. Strahilevitz, J., G. A. Jacoby, D. C. Hooper, and A. Robicsek. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009; 22: 664-689.
14. Raz R, Chazan B, Kennes Y, et al., the Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with high prevalence of TMP-SMX resistant uropathogens. Clin Infect Dis 2002;34:1165-1169.